Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma

Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma

Abstract. The international, randomized phase 3 HD15 trial established 6xeBEACOPP as standard therapy for patients with newly diagnosed advanced-stage Hodgkin lymphoma (HL) within the German Hodgkin Study Group (GHSG). We performed a follow-up analysis to assess long-term efficacy and safety of this...

Full description

Bibliographic Details
Main Authors: Andreas Engert, Helen Goergen, Jana Markova, Thomas Pabst, Julia Meissner, Josée M. Zijlstra, Zdenek Král, Dennis A. Eichenauer, Martin Soekler, Richard Greil, Stefanie Kreissl, Ruth Scheuvens, Hans Eich, Carsten Kobe, Markus Dietlein, Harald Stein, Michael Fuchs, Volker Diehl, Peter Borchmann
Format: Article
Language:English
Published: Wolters Kluwer 2017-12-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000005

Internet

http://journals.lww.com/10.1097/HS9.0000000000000005

Similar Items